Soo Yong Tan

Tan Soo Yong

  • Associate Professor, Department of Pathology
Administrative Appointment(s)
  • Head, Department of Pathology, NUS Yong Loo Lin School of Medicine
  • Chief, Department of Pathology, National University Health System
  • Group Director of Pathology, National University Health System
Joint Appointment(s)
  • Senior Principal Investigator, Institute of Cell and Molecular Biology, A*STAR
  • Head, Advanced Molecular Pathology Laboratory, Institute of Cell and Molecular Biology, A*STAR
  • Visiting Professor, University Malaya, Malaysia
  • Visiting Professor, Guangdong Academy of Medical Sciences and Guangdong Hospital, China
  • Senior Consultant, Regulatory Policy and Licensing Division, Ministry of Health, Singapore
  • Senior Consultant, Manpower Development and Professional Standards Division, Ministry of Health, Singapore
  • Visiting Consultant, Division of Medical Sciences, National Cancer Centre, Singapore
  • Visiting Consultant, National Skin Centre, Singapore
  • Chairman, Biobanking Subcommittee, Asian Network of Research Resource Centres
  • Member, Diagnostic Hotspot Advisory Panel, Exploit Technologies, A*STAR
  • Adjunct Clinician Scientist, Nanobiology Laboratory, A*STAR
  • Member, Advisory Board, MiRXES
  • Member, Hub Evaluation Panel, Diagnostic Hub, ETPL
  • Member, International Lymphoma Study Group
Academic Qualifications
  • DPhil (Oxon), Oxford University, United Kingdom
  • MBBS, National University of Singapore, Singapore
  • MRCPath, Royal College of Pathologists, United Kingdom
  • FRCPath, Royal College of Pathologists, United Kingdom
  • DMJ (Pathology), Society of Apothecaries of London, United Kingdom
  • DipRCPath, Royal College of Pathologists, United Kingdom
Research Interest(s)
  • Haematopathology
  • Haematology Oncology
  • Lymphoma
  • Leukaemia
Recent Publications
  • 1. Sayed, S., Cherniak, W., Lawler, M., Tan, S. Y., El Sadr, W., Wolf, N., . . . Fleming, K. A. (2018). Pathology and laboratory medicine in low-income and middle-income countries 2. LANCET, 391(10133), 1939-1952. doi:10.1016/S0140-6736(18)30459-8.
  • 2. Ng, S. -B., Chung, T. -H., Kato, S., Nakamura, S., Takahashi, E., Ko, Y. -H., . . . Chng, W. -J. (2018). Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. HAEMATOLOGICA, 103(2), 278-287. doi:10.3324/haematol.2017.180430.
  • 3. Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Magdalene KHK, Tan SH, Lange M, Tan SY et al. 2017 Jan. Simultaneous Inhibition of PI3K delta and PI3K alpha Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kappa B and AKT. Cancer Cell. 31(1):64-78. doi: 10.1016/j.ccell.2016.12.003.
  • 4. Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, Cai QQ, Sim KS, Nairismagi M-L, Laurensia Y et al. 2016 Sep. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology. 17(9):1240-1247. doi: 10.1016/S1470-2045(16)30148-6.
  • 5. Nairismagi ML, Tan J, Lim JQ, Nagarajan S, Ng CCY, Rajasegaran V, Huang D, Lim WK, Laurensia Y, Wijaya GC et al. 2016 Jun. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 30(6):1311-1319. doi: 10.1038/leu.2016.13.